Obseva (NASDAQ:OBSV) Upgraded by ValuEngine to “Buy”

Obseva (NASDAQ:OBSV) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports.

OBSV has been the topic of a number of other research reports. Zacks Investment Research cut shares of Obseva from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright set a $44.00 target price on shares of Obseva and gave the company a “buy” rating in a report on Wednesday, June 5th. Credit Suisse Group lowered their target price on shares of Obseva from $24.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, July 29th. Finally, Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Obseva in a report on Thursday, July 18th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Obseva presently has an average rating of “Buy” and a consensus price target of $27.50.

OBSV stock traded down $0.14 during midday trading on Thursday, reaching $8.96. 32,739 shares of the company’s stock traded hands, compared to its average volume of 48,646. The firm has a 50-day moving average price of $10.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 6.73. Obseva has a 52 week low of $8.83 and a 52 week high of $19.40. The stock has a market capitalization of $408.84 million, a price-to-earnings ratio of -4.69 and a beta of 0.92.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. On average, sell-side analysts forecast that Obseva will post -2.32 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of Obseva by 331.1% in the fourth quarter. Barclays PLC now owns 10,118 shares of the company’s stock worth $128,000 after purchasing an additional 7,771 shares during the period. Wedbush Securities Inc. increased its holdings in shares of Obseva by 86.1% in the first quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares during the period. Fosun International Ltd bought a new position in shares of Obseva in the first quarter worth $2,494,000. Geode Capital Management LLC bought a new position in shares of Obseva in the fourth quarter worth $159,000. Finally, Jane Street Group LLC bought a new position in shares of Obseva in the fourth quarter worth $218,000. 63.58% of the stock is currently owned by hedge funds and other institutional investors.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: Why do earnings reports matter?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.